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OBJECTIVE — Inexpensive and standardized methods to deliver medical education to pri-
mary care physicians (PCPs) are desirable. Our objective was to assess the impact of an individ-
ualized simulated learning intervention on diabetes care provided by PCPs.
RESEARCH DESIGN AND METHODS — Eleven clinics with 41 consenting PCPs in a
Minnesota medical group were randomized to receive or not receive the learning intervention.
Each intervention PCP was assigned 12 simulated type 2 diabetes cases that took about 15 min
each to complete. Cases were designed to remedy speciﬁc physician deﬁcits found in their
electronic medical record observed practice patterns. General linear mixed models that accom-
modated the cluster randomized study design were used to assess patient-level change from
preinterventionto12-monthpostinterventionofA1C,bloodpressure,andLDLcholesterol.The
relationshipbetweenthestudyarmandthetotalofinterventionandpatienthealthcarecostswas
also analyzed.
RESULTS — Intervention clinic patients with baseline A1C 7% signiﬁcantly improved gly-
cemic control at the last postintervention A1C measurement, intervention effect of 0.19%
mean A1C (P  0.034) and 6.7% in A1C 7% goal achievement (P  0.0099). Costs trended
lower, with the cost per patient $71 (SE  142, P  0.63) relative to nonintervention clinic
patients. The intervention did not signiﬁcantly improve blood pressure or LDL control. Models
adjusting for age, sex, and comorbidity showed similar results. PCPs reported high satisfaction.
CONCLUSIONS — A brief individualized case-based simulated learning intervention for
PCPs led to modest but signiﬁcant glucose control improvement in adults with type 2 diabetes
without increasing costs.
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A
lthough continuing medical educa-
tion (CME) is required for physi-
cian licensure in many states, there
is a paucity of evidence that traditional
methods change physician behavior or
improve clinical care (1). The Association
of American Medical Colleges has called
for increased study of CME approaches
thatincorporateadultlearningprinciples,
including tailored curricula and interac-
tiveexperiences(e.g.,simulatedactivities,
self-directed learning, immediate feed-
back)(2).Ofparticularimportanceisem-
phasis on case-based context-dependent
learning situations that address the com-
plexityofspeciﬁcclinicaldomainsandfo-
cus on transfer of knowledge and skills
beyondthespeciﬁclearningsituation(3).
Personalized outreach visit approaches
such as opinion leader interventions and
academic detailing may inﬂuence some
aspectsofclinicalcare(4,5),includingin-
creased use of aspirin and -blockers for
acutemyocardialinfarction(5),antibiotic
choices (6), and HIV prevention practices
(7). However, associated drawbacks in-
clude costs, teaching nonuniformity, and
difﬁculty ﬁnding quality opinion leaders
in nonacademic settings.
Simulated case-based learning offers
an efﬁcient and less expensive personal-
ized physician learning alternative. It has
been successful in aviation and chemical
engineering and is increasingly used in
health care training programs (8,9) to
teach Advanced Cardiac Life Support (8),
various surgical skills (10), and airway
management (11). Furthermore, our pre-
viously published evaluation of a brief
prototype of the learning intervention
used in this trial was encouraging (12).
Therefore, development and rigorous
evaluation of simulation approaches to
teach the cognitive skills of chronic dis-
ease care management are warranted.
RESEARCH DESIGN AND
METHODS
Hypothesis
This group-randomized trial was de-
signed to test whether a personalized
simulated learning intervention for phy-
sicians would improve care delivered to
adults with uncontrolled diabetes.
Study setting, subjects, and design
The study was conducted from October
2006 to May 2007 at HealthPartners
Medical Group (HPMG), a large medical
group in Minnesota that serves about
230,000 patients. Eleven HPMG clinics
were randomly selected and block ran-
domizedonthebasisofbaselinequalityof
diabetes care and number of consenting
primary care physicians (PCPs) to either
receive or not receive the intervention.
PCPs were eligible for the study if
they practiced in one of the study clinics,
provided care to at least 10 adult patients
with diabetes, and signed a consent form.
Patients were classiﬁed as having diabetes
if they had two or more outpatient diabe-
tes ICD-9 codes or used a diabetes-
speciﬁc medication in the year before
randomization (see Fig. 1 for the detailed
consort description).
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A group of PCP experts actively involved
indiabetesguidelinedevelopmentidenti-
ﬁed and reached consensus on 25 essen-
tial clinical practices for the successful
management of type 2 diabetes in adults
(Table 1). The goal of the learning pro-
gram was to promote mastery of these es-
sential clinical practices.
The research team then used existing
electronic medical record data to proﬁle
individualPCPperformanceontheessen-
tial clinical practices. If a physician per-
formed below average compared with his
or her physician peers on a clinical prac-
tice, a simulated case initialized with clin-
ical parameters designed to teach the
speciﬁc clinical practice was assigned.
Initialization parameters for the set of
learningcasesweredeﬁnedtorepresentthe
wide range of complex clinical scenarios a
PCP could encounter. Each case encom-
passed a different mix of baseline patient
demographics (age, sex, duration of diabe-
tes), medical history and comorbidities
(congestive heart failure, renal insufﬁ-
ciency,coronaryarterydisease),pharmaco-
logic use (active medications for glycemia,
blood pressure [BP], lipids, depression, as-
pirin), clinical states (A1C, BP, lipid, creat-
inine, and self-monitoring of blood glucose
results), and other subjective patient char-
acteristics (hypoglycemia symptoms, med-
ication adherence, lifestyle habits, and
depressive symptoms). An automated case
generator was developed to create distinct
simulated learning cases.
Adetaileddescriptionofthesimulation
software has been previously published
(13). The patient model embedded in the
softwareusesprespeciﬁedformulasderived
from dose-response curves for drugs, life-
style advice, and referrals. This allowed cal-
culated changes in the patient state at each
encounter on the basis of physician treat-
ment actions. The interface mimics elec-
tronic medical record screens that permit
the learner to prescribe drugs, order labs or
diagnostic tests, make referrals, give patient
advice, change frequency of recommended
self-monitoring of blood glucose testing,
view self-monitoring of blood glucose re-
sults, start or adjust insulin with each meal
and at bedtime, and see the patient at any
desired frequency for phone or ofﬁce visits.
A key strategy of the learning interven-
tionwastheindividualizationembeddedin
theinterventionatmultiplelevels.First,the
PCPsreceivedacustomizedsetofsimulated
cases selected to address their assessed
learning needs. Second, feedback resulted
from a multitude of individual provider ac-
tions, yielding a unique trajectory to each
case in response to the learner’s speciﬁc
treatment decisions. Learning feedback oc-
curred through seeing the clinical effects of
treatmentmovesatsubsequentencounters,
seeing graphic displays of the projected re-
sults of accumulated treatment actions, and
directtextualfeedbackaftereachencounter
consisting of a critique of past actions and
suggestions for future ones.
Figure 1—Diagram illustrating allocation of clinics, PCPs, and diabetes patients to the two study arms. The diagram also shows the disposition of
diabetes patients who were and were not included in the analysis. *Eligible PCPs worked 60% of a full time equivalent and had 10 patients with
diabetes. **Patients were linked to the study-consented last-assigned PCP during the preintervention period and study-consented ﬁrst-assigned PCP
during the postintervention period. Patients lacking an assigned PCP were linked to the provider seen most during the study period. PCP, primary
care physician.
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PCPs were sent an email link to the pro-
gram, accessed through a secure login
page housed on an internal server. Click-
ing on the name of one of the 12 assigned
cases started the simulation. The physi-
cian was challenged to achieve the Amer-
ican Diabetes Association–recommended
treatment goals for BP, lipids, and A1C
within 6 months of simulated time. Each
case took about 15 min to complete.
Physicians received ﬁnancial com-
pensation ($600) and up to6ho fC M E
credit for completing the program, which
had to be done on their own time. The
average number of days to complete the
12 cases was 5.5. At the end of the inter-
vention,physiciansalsoweresentaneval-
uation of the learning program.
Dependent variables
Measures of intermediate outcomes
(A1C, BP, LDL levels) of diabetes care in
patients of providers extracted from the
electronic medical record were the prin-
cipal dependent variables. The baseline
measurements were the clinical values
viewable by the provider at the ﬁrst en-
counter after completing the learning in-
tervention.ForA1CandLDL,thiswasthe
last clinical value obtained in the 1-year
preintervention period. Because of point-
of-care availability of blood pressure
levels at encounters, the baseline mea-
surement for BP was the ﬁrst value in the
1-year postintervention period. For all
measures, the last value in the postinter-
vention period is selected as the post-
intervention variable. No changes in
laboratory assay methods occurred dur-
ing the study.
Costs were estimated from the health
planperspectiveandincludedthecostsof
the intervention and health care costs. In-
tervention costs included 1) marketing to
physicians; 2) proﬁling physician learn-
ing needs; 3) implementing physician
training, case assignment, and email re-
minders; and 4) physician compensation
forcompletingcases.Healthcarecostsin-
cluded outpatient services and pharma-
ceuticals. Inpatient services were not
included because the intervention was
not expected to affect hospitalization
rates. Costs were estimated using meth-
ods previously developed to assign costs
of services in this medical setting (14).
Services were based on relative value
Table 1—The 25 essential clinical care practices taught in the simulated program
Glycemia practice Hypertension practice Lipid practice
1 Early drug initiation after medical nutrition
therapy failure
Initiation of BP medication, new diagnosis Initiation of statin above goal
2 Initiation of additional oral drugs or
exenatide beyond metformin and
sulfonylureas
Appropriate use of home BP measurements Use of ﬁbrate for high triglyceride
3 Initiation of insulin or exenatide Initiation of combo drugs for stage 2 hypertension Use of ﬁbrate for low HDL
4 Change to updated insulin regimen (basal
bolus insulin regimens)
Adding drug classes as needed Titrating statin or ezetimbe to achieve
LDL goals
5 Initiation of metformin as insulin sensitizer Initiation of fourth drug class Titrating lipid drugs, fear of myalgias
6 Initiation of thiazolidinedione as insulin
sensitizer
Titration of drugs Reassessing lipids 3 months after
adjusting lipid medications
7 Initiation of prandial insulin Target systolic BP Yearly monitoring of lipids
8 Titration of basal insulin Importance of treatment in the elderly Monitoring liver enzymes tests
9 Titration of prandial insulin More frequent visit intervals for patients not at
goal
10 Titration of insulin in large enough
amounts
Monitoring potassium and creatinine after starting
or increasing an ACE inhibitor or angiotensin
receptor blocker
11 Use of SMBGs and pattern recognition Use of ACE inhibitor or angiotensin receptor
blocker for congestive heart failure
12 Optimal metformin dosing
13 Optimal sulfonylurea dosing
14 Optimal insulin dosing
15 Optimal thiazolidinedione dosing
16 Timely visit intervals
17 Avoid severe hypoglycemia (60 mg/dl)
18 Address mild hypoglycemia (60–69 mg/dl)
19 Avoid fear of low normal glucose levels
(70–89 mg/dl)
20 A1C frequency 3 months if not at goal
21 A1C frequency 6 months at goal
22 Metformin/creatinine contraindications
23 Metformin/heart failure warnings
24 Thiazolidinedione/heart failure warnings
25 Educator referrals for patients not at goal
MNT, medical nutrition therapy; TZD, thiazolidinedione; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; SMBG, self-
monitored blood glucose; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; TG, triglyceride.
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codes recorded and priced at the 2009
physician services conversion factor of
$36.07. Costs of pharmaceuticals were
basedon68%oftheaverage2009whole-
sale price.
Independent variables
The independent variable was an indica-
tor for study arm. The interaction of this
with time was used to assess the differen-
tial impact of the intervention on the pre-
speciﬁed outcomes. Because the trial was
group-randomized at the clinic level, im-
balance in patient characteristics was ex-
pected. Patient-level independent
variables include age, sex, race, and vali-
dated indicator variables for coronary ar-
tery disease and congestive heart failure.
Adults older than 80 years and individu-
als with Charlson comorbidity scores of
3 (indicating high short-term risk of
mortality) were excluded from the study
becauseoflegitimatedebateaboutappro-
priate clinical goals in such scenarios
(15).
Statistical analysis
Attributes of study-consented physicians
andpatientslinkedtothesephysiciansare
compared by study arm using descriptive
statistics (mean, SD, proportions) and us-
ing independent sample t tests, contin-
gency tables, and Pearson 
2 tests.
General and generalized linear mixed
models with a repeated time measure-
ment (baseline and postintervention)
were used to analyze continuous and bi-
nary outcomes using SAS Proc Mixed and
Proc Glimmix. These models included a
term for study arm, time (baseline or
postintervention),atimebystudyarmin-
teraction term, and random intercepts to
accountformultiplelevelsofnesting.The
time-by-study-arm interaction term
tested the effect of the intervention arm
over time relative to the effect of the con-
trol arm over time. The analyses on test
values were also conducted predicting
postintervention values from study arm,
preintervention test value, and patient
covariates.
Denominators for the analysis of test
rates, encounter rates, and numbers of
tests and encounters include all (n 
3,417) eligible patients linked to study-
consenting physicians. Analyses for
change in values (e.g., A1C) are based on
subsets of patients who are not at goal at
baseline on particular measures of inter-
est, because they are targeted in the inter-
vention. A priori sample size calculations
assumed an analytic sample of 500 dia-
betic patients per study arm, based on 20
providers with 25 diabetic patients not at
A1C goal. Effective patient sample size
was estimated as n  291 per arm due to
clustering of patients within physicians
(estimated intraclass correlation [ICC] 
0.03). This study was designed with 80%
power to detect an A1C difference of
0.3% between study arms, with a two-
tailed 0.05. Alpha levels are not ad-
justed for testing of multiple dependent
variables.
Generalized linear models, assuming
	 distribution and a log link function,
were used to analyze the relationship be-
tween costs and study arm (16). These
models included a term for study arm,
time (baseline or postintervention), and a
time-by-study-arm interaction term. A
standardized estimate of the effect of the
intervention on costs was calculated as a
meandifferenceinpredictedcostsamong
study patients (including all patients with
A1C 7% in the preintervention period),
as they were alternatively assigned to the
intervention and control groups in the
post period. SEs were estimated using
the nonparametric bootstrap, and signiﬁ-
cance values were computed using the
percentile method (17).
Protection of human study subjects
The study was reviewed in advance, ap-
proved,andmonitoredonanongoingba-
sis by the HealthPartners Institutional
Review Board, Project #03-083.
RESULTS— Attributes of study-
eligible patients and PCPs are presented
in Table 2. Diabetic patients’ age was
56.4 
 10.7 years (mean 
 SD), 24.0%
were 65–74 years old, 48.9% were fe-
male,and29.2%werenonwhite.Atbase-
line (ﬁrst preintervention value), 47.5%
had A1C 7%, 61.7% had systolic BP
(SBP) 130 mmHg, 67.3% had diastolic
BP (DBP) 80 mmHg, and 60.2% had
LDL100mg/dl.Thenumberofdiabetic
patients per study-enrolled PCP ranged
from 10 to 125, with a mean of 56.4 

29.1.Randomizationatthecliniclevelre-
sulted in an intervention arm with a
higher proportion of younger and male
patients.
In four-level random intercept mod-
els (measurement occasion nested within
patient, provider, and clinic), ICCs at the
clinic level were generally small, with val-
ues of ICC 0.0001 for A1C and LDL
value, ICC  0.001 for SBP value, and
ICC  0.003 for DBP. Because of the low
level of variance at the clinic level, three-
Table 2—Characteristics of study physicians and diabetes patients linked to those study
physicians at intervention and control clinics
Intervention
clinics
Control
clinics P*
Patients (n) 1,847 1,570
Age (years) 55.9 
 10.9 56.9 
 10.4 0.012
Female (%) 44.6 54.0 0.001
White race (%) 72.2 69.1 0.054
Coronary artery disease during
preintervention (%) 11.3 11.3 0.97
Congestive heart failure during
preintervention (%) 3.4 4.0 0.35
Preintervention ﬁrst A1C value 7.4 
 1.7 7.5 
 1.7 0.18
Median 7.0 7.1
Preintervention ﬁrst SBP value 126.7 
 17.7 125.8 
 16.8 0.12
Median 125 124
Preintervention ﬁrst DBP value 74.0 
 10.9 73.4 
 10.6 0.12
Median 73 74
Preintervention ﬁrst LDL value 95.7 
 34.1 96.5 
 34.5 0.53
Median 92 91
PCPs (n)2 0 2 0
Age (years) 48.5 
 7.9 50.2 
 7.3 0.51
Family practice physicians (%) 45.0 45.0 0.99
Female (%) 40.0 50.0 0.53
Number of adult diabetes patients per PCP 57.0 
 28.7 55.8 
 30.2 0.90
Dataaremeans
SDunlessotherwiseindicated.*IndependentsamplesttestorPearson
2.CHF,congestive
heart failure; LDL, low-density lipoprotein cholesterol; PCP, primary care physician; DBP, diastolic blood
pressure; SBP, systolic blood pressure.
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the random intercept term for clinic.
Table3showsbaselineandfollow-up
measures of diabetes encounters, A1C,
BP,andLDLtestrates.Theyincreasedbe-
tween pre- and postintervention mea-
surements, with no differential effect for
the intervention group, as shown by the
nonsigniﬁcanttime-by-conditioninterac-
tion term P values.
Statistically signiﬁcant improvements
over time were seen within study arm for
A1C, SBP, DBP, and LDL values. Inter-
vention-arm patients had a signiﬁcantly
greater improvement (decrease) in A1C
value from baseline to postintervention
than the control arm by a value of
0.19% (95% CI 0.37 to 0.01, P 
0.034). Among patients with an A1C
7% at the last preintervention measure-
ment, 29.2% of intervention-arm and
22.5% of control-arm patients had an
A1C 7% at the last postintervention
measurement (P  0.0099, n  1,403).
There were no signiﬁcant differences in
SBP or DBP reduction over time by study
arm. Control-arm patients had a signiﬁ-
cantly greater improvement (decrease) in
LDL value from baseline to postinterven-
tion than the intervention arm by a value
of 5.1 mg/dl (95% CI 9.8 to 0.3,
P  0.039). Analysis of the proportion of
patientsatLDLgoal(100or70mg/dl
with coronary artery disease) at the last
measurement in the 12-month postinter-
vention period showed no signiﬁcant dif-
ference (0.413 intervention clinics, 0.414
control clinics, P  0.99, n  1,069).
Intervention costs were estimated to
be $27 per patient. Total costs, including
intervention and health care costs, were
estimatedtobe$71(SE142,P0.63)
lower per patient in the intervention clin-
ics compared with control clinics.
A total of 85% of intervention PCPs
completed a survey of satisfaction and
self-assessed impact of the learning. Of
these, 88% would recommend the learn-
ing experience to other physicians, 82%
thought it would help most doctors im-
prove their diabetes care skills, 82% re-
ported they would be more likely to
intensify medication for their diabetic pa-
tients, 59% would shorten their visit in-
tervals,and18%wouldstartinsulinmore
often. A separate analysis showed that
preintervention PCP performance mea-
sured by the percentage of patients at gly-
cemic goal was not a signiﬁcant predictor
of A1C postintervention (P  0.98).
CONCLUSIONS— This personal-
izedphysicianlearninginterventiondem-
onstrated a modest but signiﬁcant A1C
lowering without increasing patient visits
or total net costs. The observed A1C im-
pact (a 0.5% improvement in A1C in the
intervention group, which was 0.19%
better than the control group) is of
roughly the same magnitude as that re-
ported in uncontrolled observational
studies of more expensive interventions
intended to improve diabetes care, such
as clinical information systems (18), pa-
tient education, and disease management
programs (19). The net A1C improve-
ment is clinically signiﬁcant based on the
potentialtoreducepatientcomplications,
as demonstrated through UK Prospective
Diabetes Study results showing 37%
lower microvascular complications for
every 1% absolute A1C reduction (20).
PCPs reported high levels of satisfac-
tionwiththeintervention,repeatedlearn-
ing cases voluntarily, and reported
tangible changes in the way they manage
diabetes. The learning effect of the com-
puter-based intervention was present in-
dependent of PCP baseline diabetes
performance and indicates an ability to
transfer what was learned from the simu-
lated cases to the care of real patients—an
importantchallengeanddesirableﬁnding
in simulation research.
There are a number of points to make
about the cost of this intervention in rela-
tion to its modest clinical effectiveness.
First,theinterventiondidnotincreasepa-
tient visits or testing rates in real patients
and trended toward cost-saving. Second,
this simulated approach to physician
learning is compatible with a wide range
of chronic care improvement activities
designed to activate patients or develop
prepared care teams (21). Finally, the
simulation content can be easily adapted
to accommodate changes in care guide-
lines, discourage unnecessary tests or
treatments,andencourageuseofgenerics
and might help modulate to some degree
the high costs of diabetes care. The mar-
ginalcostsforongoinguseofthislearning
tool are relatively small and principally
involve periodic updates to ensure that
the simulation model remains current
with evidence-based treatment strategies
and newly approved drugs.
Future research should investigate
issues that might increase the impact,
reduce the complexity, or broaden the
dissemination potential of the interven-
tion. Our use of electronic medical re-
cord–based physician treatment
patterns to assess learning needs is in-
novative but can be difﬁcult. Develop-
ment of simpler methods to evaluate
physician learning needs (e.g., assess-
ment on a set of prespeciﬁed simulated
cases) warrants investigation. Second,
the intervention needs adaptation for
web distribution and to simplify addi-
tion of clinical updates when needed.
Third, at the time of this study, gener-
alized diabetes care goals, such as A1C
of 7%, were widely accepted. As per-
sonalized medicine seeks to accommo-
date individualized treatment goals,
this approach provides an opportunity
toteachasystematicapproachtosetting
clinical care goals individualized to patient
characteristics such as comorbidities,
polypharmacy concerns, hypoglycemia
risk, and genetics (22,23).
Additional work is needed to eluci-
date more precisely the mechanisms re-
sponsible for the observed effects. The
variable effect on clinical domains may be
partially related to primary emphasis on
glucose-related feedback in the learning
cases relative to BP or lipid-related feed-
back. Recent clinical trial results (23,24)
highlight the importance of directing
more attention to BP- and lipid-
management issues. It is notable that the
studysitehadrelativelygoodbaselinelev-
els of A1C, BP, and LDL (25). The impact
of this learning intervention in settings
withworsebaselinelevelsofdiabetescare
remainstobedetermined.Thispromising
care-improvement strategy might also be
applied to other clinical domains.
Despite some limitations, these data
demonstrate that delivery of a brief and
relatively inexpensive individualized
physicianlearninginterventionimproved
intermediate outcomes of diabetes care
without increasing costs. Experimenta-
tionwithsimulatedpersonalizedlearning
interventions in a broad range of other
care or educational settings seems
warranted.
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